Prevention of chemotherapy-induced peripheral neuropathy: A matter of personalized treatment?

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1424-1426

  Postma, T J ^a   Reijneveld, J C ^a   Heimans, J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CYTOCHROME P450 2C8; DIHYDROPYRIMIDINE DEHYDROGENASE; PACLITAXEL; PLATINUM PLUS TAXANE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CLINICAL PRACTICE; COHORT ANALYSIS; COLORECTAL CANCER; DIARRHEA; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; OVARY CANCER; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84878468848     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt173     Document Type: Editorial

References (25)

1. Markman M. Chemotherapy-induced peripheral neuropathy: an increasing concern for oncologists. Curr Oncol Rep 2005; 7: 159-160.
2. Argyriou AA, Bruna J, Marmiroli P et al. Chemotherapy-induced peripheral neuropathy (CIPN): an update. Crit Rev Oncol Hematol 2012; 82(1): 51-77.
3. Markman M. Clinical response versus clinical benefit in oncology: not necessarily equivalent terms. J Cancer Res Clin Oncol 1997; 123: 363-364.
4. Verstappen CC, Heimans JJ, Hoekman K et al. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003; 63(15): 1549-1563.
5. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012; 14(Suppl 4): 45-54.
6. Gamelin L, Boisdron-Celle M, Morel A et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008; 26(7): 1188-1190.
7. Grothey A, Nikcevich DA, Sloan JA et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011; 29(4): 421-427.
8. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002; 249: 9-17.
9. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006; 42(1): 24-30.
10. Mielke S. Individualized chemotherapy with paclitaxel. Curr Opin Oncol 2007; 19 (6): 585-589.
11. Cavaletti G, Alberta P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 2011; 12: 1151-1161.
12. Hertz DL, Roy S, Motsinger-Reif AA et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 2013; 24: 1472-1478.
13. Gréen H, Söderkvist P, Rosenberg P et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 2009; 104(2): 130-137.
14. Leskelä S, Jara C, Leandro-Garcia LJ et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics 2011; 112(2): 121-129.
15. Hertz DL, Motsinger-Reif AA, Drobish A et al. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 2012; 134(1): 401-410.
16. Marsh S, Paul J, King CR et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomized trial in ovarian cancer. J Clin Oncol 2007; 25: 4528-4535.
17. Deenen MJ, Tol J, Burylo AM et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17(10): 3455-3468.
18. Cornblath DR, Chaudhry V, Carter K et al. Total neuropathy score: validation and reliability study. Neurology 1999; 53(8): 1660-1664.
19. Frigeni B, Piatti M, Lanzani F et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst 2011; 16(3): 228-236.
20. Postma TJ, Heimans JJ, Muller MJ et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998; 9: 739-744.
21. Griffith KA, Merkies IS, Hill EE et al. Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 2010; 15: 314-325.
22. Calhoun EA, Welshman EE, Chang CH et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group- Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003; 13(6): 741-748.
23. Postma TJ, Aaronson NK, Heimans JJ et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005; 41(8): 1135-1139.
24. The CI-PERINOMS study group. CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study. J Peripher Nerv Syst 2009; 14: 69-71.
25. Cavaletti G, Cornblath DR, Merkies IS et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 2013; 24(2): 454-462.